ASCO Abstract Preview: ImClone, Genentech

Abstract No 5520: A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab vs. carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.

Abstract No. 1026: Results of a phase II trial of trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer who had progressed during trastuzumab therapy.

---

Genvec GNVC:

Abstract No. 6067: A phase I dose escalation study of Ad GV.EGR.TNF.11D with concurrent chemoradiotherapy in patients with recurrent head and neck cancer.

---

ImClone Systems:

Abstract No. 3: FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) vs. CV alone in the first-line treatment of patients with advanced non-small-cell lung cancer. (Note: Will not be available online May 15.)

Abstract No. LBA4011: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group.

Abstract No. 2: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. (Note: Will not be available online May 15.)

---

Immunogen IMGN:

Abstract No. 1028: A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer.

---

Incyte INCY:

Abstract No. 7004: A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF).